Premenopausal women experience a lower incidence of cardiovascular disease as compared to age-matched men, partially due to the cardioprotective effects of estrogen. Acute inflammation increases pro-inflammatory cytokine production and reduces nitric oxide bioavailability, resulting in impaired vascular function. Estrogen has both anti-inflammatory and pro-vasodilatory properties. During the high estrogen mid-luteal phase of the menstrual cycle, sex differences in vascular function and inflammatory responses to induced inflammation have been observed in premenopausal women as compared with age-matched men. However, limited knowledge exists regarding sex differences in estrogen independent responses to acute inflammation. Thus, our objective was to evaluate sex differences in vascular responses to induced inflammation- with a reduced influence of estrogen concentration. Due to the dampening of estrogen-related anti-inflammatory and pro-vasodilatory effects when estrogen concentrations are low, we hypothesized that women would experience a greater inflammatory response as compared with men and that women and men would exhibit similar vascular function. In a double-blind crossover sham-controlled study of 15 women (21 ± 3y) and 15 men (21 ± 2y), we assessed pro-inflammatory interleukin-6 concentration ([IL-6]) and vascular function via brachial artery flow-mediated dilation (FMD) at baseline (BL), 24 hours (24H), and 48 hours (48H) after influenza vaccine administration. Women were studied when circulating estrogen levels are typically low (early follicular phase or placebo pill phase of oral contraceptive pills) and similar between sexes. Following induced inflammation, both sexes exhibited an increase in [IL-6] at 24H (BL v 24H: women p=0.0049; men p=0.0015) that returned to near baseline levels by 48H (BL v 48H: women p=0.43; men p=0.29; [IL-6] (pg/mL): women BL: 0.56 ± 0.5, 24H: 1.14 ± 0.7, 48H: 0.59 ± 0.4; men BL: 0.38 ± 0.2, 24H: 1.05 ± 0.7, 48H: 0.56 ± 0.2). There were no sex differences in FMD or [IL-6] at any time point (FMD: sex p=0.062, time p=0.30, interaction p=0.25; FMD (%): women BL: 8.33 ± 4.8, 24H: 6.40 ± 4.4, 48H: 9.05 ± 5.5; men: BL: 5.25 ± 2.9, 24H: 6.14 ± 2.1, 48H: 6.71 ± 1.1; [IL-6]: BL: p=0.38, 24H: p=0.57, 48H: p=0.99). Notably, women exhibited significantly lower resting brachial artery diameter (BL D; p<0.0001 all time points) than men (BL D (mm): women BL: 3.22 ± 0.4, 24H: 3.18 ± 0.4, 48H: 3.19 ± 0.4; men BL: 4.07 ± 0.6, 24H: 4.24 ± 0.4, 48H, 4.22 ± 0.4). Due to sex difference in baseline diameter, we allometrically scaled FMD to normalize the flow-mediated response to variability in baseline diameter between the sexes. However, there were no sex differences in allometrically scaled FMD (sex p=0.11, time p=0.20, interaction p= 0.072; Scaled FMD (%): women BL: 6.39 ± 3.7, 24H: 4.32 ± 3.8, 48H: 6.92 ± 3.7; men BL: 7.03 ± 3.9, 24H: 8.71 ± 4.2, 48H: 8.69 ± 4.3). When estrogen concentrations are low, women show similar inflammatory responses and vascular function as compared with age-matched men, suggesting a primary role of estrogen in previously observed sex differences in inflammatory responses and vascular function.
Read full abstract